ADAR1 Capital Management, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001940272

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2026 · 253 positions · Total reported value $1.82B · Top-10 concentration 36.9% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 47.5% · 33 new · 62 cut · 48 exited

Active Share (vs S&P 500): 98.9% · vs QQQ: 99.4% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -7.0% · vs SPY -9.1% · Prev Value $1.81B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -3.7% · vs SPY -5.9% · Latest Value $1.82B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, ADAR1 Capital Management, LLC disclosed 253 equity positions with a combined reported value of $1.82B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 36.9% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were SPY ($135.46M), PTGX ($134.04M), ROIV ($112.62M). By sector, the heaviest allocations are Health Care 84.5%, Financials 3.3%. Versus the prior quarter, allocation shifted toward Other (+1.4pp), Financials (+0.7pp) and away from Health Care (-2.0pp).

Versus the prior quarter, ADAR1 Capital Management, LLC opened 33 new positions, trimmed 62 and fully exited 48, a turnover rate of 47.5% of positions. The portfolio's overlap with the prior quarter was 73% of names.

The largest new positions opened in Q3 2026 were ABCL ($12.00M), BEAM ($10.29M), ENTX ($7.64M).

Of the 48 positions fully exited versus the prior quarter, the largest were ZLAB ($64.01M), CRNX ($45.73M), IWM ($18.78M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • ABCL ABCELLERA BIOLOGICS INC · $12.00M
  • BEAM BEAM THERAPEUTICS INC · $10.29M
  • ENTX ENTERA BIO LTD · $7.64M
  • KRSP RICE ACQUISITION CORP 3 · $7.55M
  • DXYZ DESTINY TECH100 INC · $6.49M
  • DARE YARROW BIOSCIENCE INC · $6.37M
  • TLGYF TCGX ACQUISITION CORP · $6.26M
  • RACD RESEARCH ALLIANCE CORP IV · $6.22M

Fully Exited (vs previous quarter)

  • ZLAB ZAI LAB LTD · prev qtr: $64.01M
  • CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $45.73M
  • IWM ISHARES TR · prev qtr: $18.78M
  • XBI SPDR SERIES TRUST · prev qtr: $10.67M
  • XENE XENON PHARMACEUTICALS INC · prev qtr: $10.05M
  • FTH FAETH THERAPEUTICS INC · prev qtr: $9.03M
  • PCSC PERCEPTIVE CAP SOLUTIONS COR · prev qtr: $7.34M
  • BHF BRIGHTHOUSE FINL INC · prev qtr: $6.05M

Insider Transactions (Form 4)

Latest ADAR1 Capital Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-11 Buy NextCure, Inc. 12,333 $5.10 SEC filing
2026-11-06 Buy NextCure, Inc. 3,662 $5.10 SEC filing
2026-11-05 Buy InMed Pharmaceuticals Inc. 2,640 $13.10 SEC filing
2026-11-05 Buy NextCure, Inc. 1,024 $5.10 SEC filing
2026-10-27 Buy NextCure, Inc. 3,553 $5.10 SEC filing
2026-10-26 Buy NextCure, Inc. 1,672 $5.03 SEC filing
2026-10-23 Buy InMed Pharmaceuticals Inc. 4 $1.32 SEC filing
2026-10-23 Buy NextCure, Inc. 5,626 $4.83 SEC filing

All insider transactions →

Fund Profile

ADAR1 Capital Management, LLC is an SEC-registered 13F filer based in Austin, TX, United States. As of Q2 2026 it reported 268 US equity positions with a combined value of $1.81B. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).

Firm Snapshot

  • Headquarters: AUSTIN, TX, United States
  • SEC registration: 801-130082 (status: Approved), registered 2024-04-25
  • Regulatory AUM (Form ADV): $1.68B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 2 hedge funds

Portfolio Structure

  • 268 positions · $1.81B reported value (Q2 2026)
  • Top 10 holdings = 34.2% of reported value
  • Largest position: PTGX (PROTAGONIST THERAPEUTICS INC) at 6.5%
  • Average position size: $6.74M

Sector Tilt

  • Health Care 86.5%
  • Financials 2.6%
  • Industrials 0.4%
  • (classified holdings cover 90% of value)

Quarterly Activity

  • Q2 2026: 42 new, 99 added, 60 reduced, 69 exited
  • 67 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: Aggressive growth tilt, with significant new positions (33) and a 7x increase in SPY exposure, suggesting bullish market sentiment and tactical diversification. 2. Key moves: - Added: SPY (7.44% wt, +610.5% shares), DNLI (2.35% wt, +101.3% shares), SEPN (2.09% wt, +3.6% shares), AURA (1.86% wt, +4038.1% shares). - Reduced: PTGX (7.36% wt, -1.0% shares), ROIV (6.18% wt, -2.5% shares), IMVT (3.92% wt, -9.2% shares), AGIO (2.08% wt, -11.5% shares). 3. Portfolio structure: Active, biotech/Health Care-heavy (80% of top 10), high-risk (small/mid-cap biotech names), with a modest passive overlay (SPY). 4. Per-holding one-liner: - SPY: S&P 500 ETF (benchmark). - PTGX: Biopharma (unverified). - ROIV: Biotech (unverified). - IMVT: Biotech (unverified). - DNLI: Neurology biotech (unverified). - BOXX: EA Trust (unverified). - SEPN: Gastroenterology biotech (unverified). - AGIO: Cancer metabolism biotech (unverified). - AURA: Oncology biotech (unverified). - INSM: Rare disease biotech (unverified). 5. Style summary: High-conviction biotech bets with opportunistic S&P 500 exposure.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 04:26

Sector Allocation

Health Care 84.5%
Financials 3.3%
Other 11.8%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 177.62K $135.46M 7.44%
7.44%
Add
2 951.40K $134.04M 7.36%
7.36%
Reduce
3 3.08M $112.62M 6.18%
6.18%
Reduce
4 2.12M $71.46M 3.92%
3.92%
Reduce
5 2.07M $42.83M 2.35%
2.35%
Add
6 337.12K $39.91M 2.19%
2.19%
Hold
7 974.40K $38.13M 2.09%
2.09%
Add
8 1.14M $37.89M 2.08%
2.08%
Reduce
9 5.39M $33.82M 1.86%
1.86%
Add
10 229.53K $26.20M 1.44%
1.44%
Hold
11 799.30K $25.91M 1.42%
1.42%
Add
12 3.24M $25.15M 1.38%
1.38%
Add
13 6.65M $24.60M 1.35%
1.35%
Add
14 2.16M $24.14M 1.32%
1.32%
Reduce
15 2.01M $23.65M 1.30%
1.30%
Add
16 1.73M $22.85M 1.25%
1.25%
Add
17 8.89M $22.84M 1.25%
1.25%
Hold
18 237.57K $21.15M 1.16%
1.16%
Reduce
19 442.68K $20.29M 1.11%
1.11%
Add
20 813.24K $19.28M 1.06%
1.06%
Add
21 464.60K $19.16M 1.05%
1.05%
Add
22 87.51K $17.96M 0.99%
0.99%
Hold
23 952.06K $17.35M 0.95%
0.95%
Add
24 637.35K $17.32M 0.95%
0.95%
Add
25 997.36K $15.96M 0.88%
0.88%
Reduce
26 926.35K $15.93M 0.88%
0.88%
Hold
27 258.18K $15.63M 0.86%
0.86%
Add
28 369.79K $15.02M 0.82%
0.82%
Add
29 3.06M $14.90M 0.82%
0.82%
Add
30 179.03K $14.26M 0.78%
0.78%
Reduce
31 823.88K $14.24M 0.78%
0.78%
Add
32 138.66K $13.20M 0.72%
0.72%
Add
33 1.52M $12.76M 0.70%
0.70%
Reduce
34 1.14M $12.60M 0.69%
0.69%
Add
35 392.42K $12.57M 0.69%
0.69%
Add
36 16.45K $12.47M 0.69%
0.69%
Reduce
37 135.59K $12.43M 0.68%
0.68%
Hold
38 6.52M $12.33M 0.68%
Form 4 · 3 →
0.68%
Add
39 1.01M $12.02M 0.66%
0.66%
Add
40 822.16K $12.00M 0.66%
0.66%
New
41 185.62K $11.91M 0.65%
0.65%
Hold
42 5.71M $11.73M 0.64%
0.64%
Reduce
43 4.56M $11.36M 0.62%
0.62%
Reduce
44 397.72K $11.33M 0.62%
0.62%
Add
45 276.35K $10.94M 0.60%
0.60%
Reduce
46 366.97K $10.68M 0.59%
0.59%
Add
47 1.00M $10.52M 0.58%
0.58%
Hold
48 420.98K $10.29M 0.56%
0.56%
New
49 531.35K $10.14M 0.56%
0.56%
Reduce
50 100.00K $9.95M 0.55%
0.55%
Reduce

FAQ

What did ADAR1 Capital Management, LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, ADAR1 Capital Management, LLC reported 253 equity positions worth $1.82B in aggregate; its largest disclosed positions were SPY ($135.46M), PTGX ($134.04M), ROIV ($112.62M).

How large is ADAR1 Capital Management, LLC's portfolio?

ADAR1 Capital Management, LLC reported $1.82B of long equity holdings across 253 positions as of 2026-Q3. Top-10 holdings account for 36.9% of reported value.

What is ADAR1 Capital Management, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/adar1-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →